Navigation Links
Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
Date:2/19/2008

BRISTOL, Tenn., Feb. 19 /PRNewswire/ -- Graceway Pharmaceuticals, LLC ("Graceway"), a portfolio company of GTCR Golder Rauner, LLC, announced today that it has acquired all of the assets related to Estrasorb(R) (estradiol topical emulsion) in North America from Novavax, Inc. ("Novavax") (Nasdaq: NVAX) and Allergan, Inc. ("Allergan") (NYSE: AGN). Estrasorb is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause and is available by prescription only.

The agreements between Novavax and Graceway provide for the sale by Novavax of the patent associated with the product, the sale of other intellectual properties (including trademarks, copyrights, know-how and related assets), and the sale of all production and packaging equipment related to Estrasorb. Graceway will license back to Novavax rights to its micellar nanoparticle technology for application in fields unrelated to Estrasorb. The license is free of royalties. Novavax and Graceway have also executed a supply agreement under which Novavax will manufacture additional finished goods of Estrasorb for a limited period.

In a separate but related transaction, Graceway has also purchased from Allergan the New Drug Application for the Estrasorb product, raw material and finished goods inventories, and any tangible and intangible assets related to the product. Simultaneous with the transaction between Novavax and Graceway, Allergan has terminated all of its previously licensed rights to commercialize the product. Following the transaction, Allergan will have no continuing role with the product. All rights to make or have made, develop, commercialize and sell the Estrasorb product in North America are now held by Graceway.

About Graceway Pharmaceuticals, LLC

Graceway Pharmaceuticals, LLC ("Graceway"), headquartered in Bristol, Tennessee, is a pharmaceutical company focused on acquiring, in-licensing, and developing branded prescription pharmaceutical products. Current prescription products marketed by Graceway include Aldara(R) (imiquimod) Cream 5%, Maxair(R) Autohaler(R) (pirbuterol acetate inhalation aerosol), Atopiclair(R) Nonsteroidal Cream, and Benziq(R)(benzoyl peroxide). Aldara, Maxair, Autohaler, and Tambocor are trademarks owned by or licensed to Graceway.

About GTCR Golder Rauner, LLC

Founded in 1980, GTCR Golder Rauner, LLC ("GTCR") is a leading private equity investment firm and long-term strategic partner for outstanding management teams. The Chicago-based firm pioneered the investment strategy of identifying and partnering with exceptional executives to acquire and build companies through a combination of acquisitions and strong internal growth. GTCR currently manages more than $8 billion of equity capital invested in a wide range of companies and industries. More information about GTCR may be found at http://www.gtcr.com.

Contact:

Graceway Pharmaceuticals, LLC:

John Bellamy

Executive Vice President & General Counsel

(423) 274-2100

Russo Partners, LLC:

Wendy Lau

(212) 845-4272


'/>"/>
SOURCE Graceway Pharmaceuticals, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
2. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
3. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
4. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
5. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
7. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
8. CYIG Awarded Chinas "Top 100 Enterprises" in New Pharmaceuticals, Selected as National "Torch Plan Key High-Tech Enterprise"
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2017)... ... , ... In response to the strong base of evidence supporting the use ... release of their Gait Trainer 3 with an Integrated Music Therapy option. This is ... in rehabilitating individuals with cerebral palsy, traumatic brain injury, stroke and Parkinson’s disease. ...
(Date:5/18/2017)... ... 18, 2017 , ... Dr. Ralph Mobbs of the Neuro ... Wales Private Hospital. The procedure was performed on a 46-year-old male patient suffering ... prior to undergoing surgery. , The AxioMed viscoelastic disc is a next-generation disc ...
(Date:5/18/2017)... ... ... Clinical Supplies Management (“CSM”), a Great Point Partners II (“GPP”) portfolio company, ... has doubled in size over the past six months with the acquisition of businesses ... joins CSM as Chief Financial Officer. Roger has over 25 years of experience ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... and further enhances its scientific power by providing investigators access to a ... agreed to join the scientific advisory board. “We are committed to offering ...
Breaking Biology Technology:
(Date:4/19/2017)... 2017 The global military biometrics ... marked by the presence of several large global players. ... five major players - 3M Cogent, NEC Corporation, M2SYS ... nearly 61% of the global military biometric market in ... global military biometrics market boast global presence, which has ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... Report on Form 10-K on Thursday April 13, 2017 with the ... The ... section of the Company,s website at http://www.nxt-id.com  under "SEC Filings," ... 2016 Year Highlights: Acquisition of ...
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):